Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential genotype dependent inhibition of CYP2C9 in humans.

Drug metabolism and disposition: the biological fate of chemicals - 1 Jul 2008

Kumar Vikas, Brundage Richard C, Oetting William S, Leppik Ilo E, Tracy Timothy S

Abstract excerpt

The effects of genetic polymorphisms in drug-metabolizing enzymes (e.g., CYP2C9(*)3) on drug clearance have been well characterized but much less is known about whether these polymorphisms alter susceptibility to drug-drug interactions. Previous in vitro work has demonstrated that genotype-depend...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Aryl Hydrocarbon Hydroxylases
Share to Cross-Over Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Enzyme Inhibitors

Share to Fluconazole

Share to Genotype

Share to Reference Values

Source

Open in PubMed Open full text

Identifiers

PMID: 18378563
DOI: 10.1124/dmd.108.020396
PMCID: PMC2435413

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18378563-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential genotype dependent inhibition of CYP2C9 in humans.PMID 18378563Read ↗

Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes.Semantic proximity Read ↗

A model-based analysis of the CYP2C9 genotype effects on fluconazole inhibition using flurbiprofen, ketoprofen and tolbutamide as probe drugs.Semantic proximity Read ↗

CYP2C9 genotype as a predictor of drug disposition in humans.Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.Semantic proximity Read ↗

Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects.Semantic proximity Read ↗

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.Semantic proximity Read ↗

CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variant.Semantic proximity Read ↗

The impact of CYP2C19 genotype on phenoconversion by concomitant medicationSemantic proximity Read ↗

Clinical consequences of cytochrome P450 2C9 polymorphisms.Semantic proximity Read ↗

Physiologically based pharmacokinetic (PBPK) modeling of flurbiprofen in different CYP2C9 genotypes.Semantic proximity Read ↗

Phenoconversion Due to Drug-Drug Interactions in CYP2C19 Genotyped Healthy Volunteers.Semantic proximity Read ↗

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.